Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research

References

• Substance Abuse and Mental Health Services Administration. Results from the 2012 national survey on drug use and health: National findings. Rockville: Office of Applied Studies. 2013
   Google Scholar
• Chen K, Scheier LM, Kandel DB. Effects of chronic cocaine use on physical health: a prospective study in a general population sample. Drug Alcohol Depend 1996;43:23-37
   PubMed Web of Science ®Google Scholar
• Hando J, Howard J, Zibert E. Risky drug practices and treatment needs of youth detained in New South Wales Juvenile Justice Centres. Drug Alcohol Rev 1997;16:137-45
   PubMed Web of Science ®Google Scholar
• Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997;46:105-13
   PubMed Web of Science ®Google Scholar
• Richards JR, Bretz SW, Johnson EB, et al. Methamphetamine abuse and emergency department utilization. West J Med 1999;170:198-202
   PubMedGoogle Scholar
• Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010;122:2558-69
   PubMed Web of Science ®Google Scholar
• Vearrier D, Greenberg MI, Miller SN, et al. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon 2012;58:38-89
   PubMed Web of Science ®Google Scholar
• Rounsaville BJ, Anton SF, Carroll K, et al. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991;48:43-51
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2009 national survey on drug use and health: National findings. Rockville: Office of Applied Studies. 2010
   Google Scholar
• Van Tieu H, Koblin BA. HIV, alcohol, and noninjection drug use. Curr Opin HIV AIDS 2009;4:314-18
   PubMed Web of Science ®Google Scholar
• Greberman SB, Wada K. Social and legal factors related to drug abuse in the United States and Japan. Public Health Rep 1994;109:731-7
   PubMedGoogle Scholar
• Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev 2011;12:CD002950
   Google Scholar
• Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008;2:CD006754
   Google Scholar
• Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007;3:CD006306
   Google Scholar
• Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2011;7:12
   PubMedGoogle Scholar
• Castells X, Casas M, Pérez-Mañá C, et al. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2010;2
   Google Scholar
• Rush CR, Stoops WW. Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem 2012;4:245-65
   PubMed Web of Science ®Google Scholar
• Stoops WW, Rush CR. Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des 2013;19(40):7026-35
   PubMedGoogle Scholar
• Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract 2011;24(6):541-50
   PubMedGoogle Scholar
• Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994;26:119-28
   PubMed Web of Science ®Google Scholar
• Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and damphetamine in non-drug-abusing humans. J Clin Psychopharmacol 2001;21:273-86
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PE, Fillmore MT, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18:534-43
   PubMed Web of Science ®Google Scholar
• Burgess MJ, Kasten MJ. Human immunodeficiency virus: what primary care clinicians need to know. Mayo Clin Proc 2013;88(12):1468-74
   PubMed Web of Science ®Google Scholar
• Halpern B, Faria AM, Halpern A. Fixed-dose combination of phentermine-topiramate for the treatment of obesity. Expert Rev Clin Pharmacol 2013;6(3):235-41
   PubMed Web of Science ®Google Scholar
• Meneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med 2013;126(9 Suppl 1):28-37
   PubMedGoogle Scholar
• Neldam S, Dahlöf B, Oigman W, Schumacher H. Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals. Int J Clin Pract 2013;67(9):843-52
   PubMedGoogle Scholar
• Rogóż Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep 2013;65(6):1535-44
   PubMed Web of Science ®Google Scholar
• Sachs GS, Peters AT, Sylvia L, Grunze H. Polypharmacy and bipolar disorder: what’s personality got to do with it? Int J Neuropsychopharmacol 2013;26:1-9
   Google Scholar
• Goeders NE, Guerin GF. Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav 2008;91(1):181-9
   PubMedGoogle Scholar
• Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-6
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-81
   PubMed Web of Science ®Google Scholar
• Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009;101:34-41
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013;70(12):1338-46
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013;133(1):94-9
   PubMed Web of Science ®Google Scholar
• Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 2000;406:1-13
   PubMed Web of Science ®Google Scholar
• Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008;75(1):218-65
   PubMed Web of Science ®Google Scholar
• Kalivas PW. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004;4(1):23-9
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 2006;6(17):1845-59
   PubMedGoogle Scholar
• Ritz MC, Lamb RJ, Goldberg SR, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-23
   PubMed Web of Science ®Google Scholar
• Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007;32(7):1433-51
   PubMed Web of Science ®Google Scholar
• Tiffany ST, Singleton E, Haertzen CA, et al. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993;34:19-28
   PubMed Web of Science ®Google Scholar
• Chadwick MJ, Gregory DL, Wendling G. A double-blind amino acids, L-tryptophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. Am J Drug Alcohol Abuse 1990;16(3-4):275-86
   PubMed Web of Science ®Google Scholar
• Carroll KM, Kiluk BD, Nich C, et al. Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend 2014. [Epub ahead of print]
   Google Scholar
• Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88(2-3):214-23
   PubMedGoogle Scholar
• Woolverton WL. Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. Pharmacol Biochem Behav 1987;26:835-9
   PubMedGoogle Scholar
• Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfirm and Alpha1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013;23:1401-7
   PubMed Web of Science ®Google Scholar
• Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319:561-9
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012;100(4):801-10
   PubMed Web of Science ®Google Scholar
• Shorter D, Kosten TR. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med 2011;9:119
   PubMed Web of Science ®Google Scholar
• Yoo JH, Kitchen I, Bailey A. The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us? Br J Pharmacol 2012;166(7):1993-2014
   PubMedGoogle Scholar
• Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72(11):950-6
   PubMed Web of Science ®Google Scholar
• Rotheram-Fuller E, De La Garza R, Mahoney JJ, et al. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Res 2007;152(2-3):205-10
   PubMedGoogle Scholar
• Sofuoglu M, Singha A, Kosten TR, et al. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav 2003;75(4):801-8
   PubMedGoogle Scholar
• Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006;85(2):129-37
   PubMedGoogle Scholar
• Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008;33(5):651-67
   PubMedGoogle Scholar
• Schmitz JM, Rathnayaka N, Green CE, et al. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry 2012;3:77
   PubMedGoogle Scholar
• Giannini AJ, Billett W. Bromocriptine-desipramine protocol in treatment of cocaine addiction. J Clin Pharmacol 1987;27(8):549-54
   PubMedGoogle Scholar
• Kablinger AS, Lindner MA, Casso S, et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol 2012;26(7):973-81
   PubMedGoogle Scholar
• Jayaram-Lindström N, Wennberg P, Beck O, Franck J. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry 2005;59(3):167-71
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008;165(11):1442-8
   PubMedGoogle Scholar
• Marks KR, Lile JA, Stoops WW, Rush CR. Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users. Psychopharmacology (Berl) 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010;20(11):823-8
   PubMed Web of Science ®Google Scholar
• Ling W, Shoptaw S, Hillhouse M, et al. Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction 2012;107(2):361-9
   PubMed Web of Science ®Google Scholar
• Urschel HC, Hanselka LL, Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol 2011;25(2):254-62
   PubMed Web of Science ®Google Scholar
• McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012;18(5):414-18
   PubMed Web of Science ®Google Scholar
• Winchell C, Rappaport BA, Roca R, et al. Reanalysis of methamphetamine dependence treatment trial. CNS Neurosci Ther 2012;18:367-8
   PubMedGoogle Scholar
• Beitz J. Trial endpoints for drug approval in oncology: chemoprevention. Urology 2001;57:213-15
   PubMedGoogle Scholar
• Abadie E, Ethgen D, Avouac B, et al. Group for the Respect of Excellence and Ethics in Science. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthr Cartil 2004;12:263-8
   PubMed Web of Science ®Google Scholar
• Carroll KM, Rounsaville BJ, Nich C, et al. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994;51(12):989-97
   PubMed Web of Science ®Google Scholar
• Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93(5):713-27
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63(2):219-28
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Mooney ME, Moeller FG, et al. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008;94(1-3):142-50
   PubMedGoogle Scholar
• Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010;18(3):238-44
   PubMedGoogle Scholar
• Comer SD, Ashworth JB, Foltin RW, et al. The role of human drug self administration procedures in the development of medications. Drug Alcohol Depend 2008;96:1-15
   PubMedGoogle Scholar
• Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology(Berl) 2008;199:403-19
   PubMed Web of Science ®Google Scholar
• Igua AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy 2014;7:35-44
   PubMedGoogle Scholar
• Galloway GP, Coyle JR, Guillèn JE, et al. A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones. J Addict Med 2011;5:170-4
   PubMedGoogle Scholar
• Rothman RB, Blough BE, Baumann MH. Dopamine/serotonin releasers as medications for stimulant addictions. Prog Brain Res 2008;172:385-406
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: A randomized trial. JAMA 2014;311(2):155-63
   PubMed Web of Science ®Google Scholar
• Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther 2012;29(5):385-400
   PubMed Web of Science ®Google Scholar